Healthy Clinical Trial
Official title:
A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, SAD and MAD Study to Measure the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT125134 in Healthy Subjects
The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125134 and its active metabolite CORT125201 after single and multiple ascending oral doses of CORT125134 in healthy participants.
This is a 3-part, single-center study of single and multiple ascending doses of CORT125134 in
healthy participants.
Part I is a single dose study. Initially, participants will be enrolled sequentially into 1
of up to 6 cohorts, each containing 10 participants, in a double-blind, randomized,
placebo-controlled assessment of single-ascending doses (SAD) of CORT125134. Within each
cohort, 8 participants will be randomly assigned to receive a single dose of CORT125134, and
2 participants will be randomly assigned to receive a single dose of matching placebo.
Thereafter, Cohort 7 will be a food-effect cohort, in which all 8 participants will receive a
single dose of CORT125134 after a high-fat breakfast (open label). Cohorts 8 and 9 will be
pharmacological effect cohorts, in each of which 10 participants will receive a challenge
agent (prednisone, 25 mg) alone on Day -19; with an active comparator (mifepristone, 600 mg)
on Day -12, and with CORT125134 on Day 1 in an open-label single sequence crossover design.
Pharmacological effects will be explored by measuring effects on peripheral blood eosinophil,
lymphocyte and neutrophil counts, serum osteocalcin, assay of messenger ribonucleic acid
(mRNA) expression of FK506 Binding Protein 5 (FKBP5) and Glucocorticoid-induced Leucine
Zipper (GILZ) in whole blood (proof of pharmacological effect Cohort 8) and by measuring
effects on oral glucose tolerance (proof of concept Cohort 9).
Part 2 and 3 will be double-blind, randomized, placebo-controlled assessments of multiple
oral ascending doses (MAD) of CORT125134. Participants will be enrolled sequentially into 1
of up to 4 cohorts (Cohorts 10-13), each containing 12 participants. Within each cohort, 9
participants will be randomly assigned to receive CORT125134 and 3 participants to receive
matching placebo daily for 14 days (Days 1-14). The effects of CORT125134 on response to
prednisone challenge will be additionally explored in Cohorts 12 and 13 in a single sequence
crossover, with prednisone being given alone on Day -5 and in combination with CORT125134 or
placebo on Day 14.
Throughout the study, routine safety tests and assessments of PK (CORT125134 and CORT125201)
will be performed, and changes in serum cortisol and plasma adrenocorticotrophic hormone
(ACTH) measured.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |